Form 4: IDEAYA Biosciences Officer Trades IDEAYA

IDEAYA Biosciences Chief Accounting Officer Andres Ruiz Briseno reports a 10b5-1 plan transaction involving the acquisition and sale of common stock.

Summary

• Andres Ruiz Briseno, Chief Accounting Officer at IDEAYA Biosciences, Inc., executed a transaction on July 7, 2026, under a Rule 10b5-1 trading plan adopted on December 19, 2025.
• The transaction involved the acquisition of 9,550 shares of common stock at a price of $12.86 per share.
• Concurrently, 9,550 shares of common stock were sold at a weighted average price of $40.0137, with individual sale prices ranging from $40.00 to $40.10.
• Following these transactions, Mr. Briseno beneficially owns 26,466 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider stock transactions executed under a pre-defined plan, without significant new strategic information or financial performance indicators.

Positives

• The transaction was executed under a pre-established Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to stock transactions.
• The acquisition of shares at a lower price ($12.86) and sale at a higher price ($40.0137) suggests a profitable execution of the plan.

Negatives

• A significant number of shares (9,550) were sold, which could be interpreted as a reduction in the officer's direct stake in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving Rule 10b5-1 plans, are common for executives looking to diversify or manage their personal finances in a pre-planned manner, aiming to avoid insider trading concerns. The execution of such a plan by a Chief Accounting Officer is standard practice.

Stakeholder Impact

• Shareholders: The sale of shares by a key officer might be perceived negatively, although it was conducted under a pre-planned Rule 10b5-1, mitigating concerns of opportunistic selling.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, Chief Accounting Officer, Beneficial Ownership